SPRB · Spruce Biosciences, Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Aug 7, 2025; bars on opposite sides are not compared.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRB
this stock
Spruce Biosciences, Inc.
|
$160.20M | -36.0% | -100.0% | — | 14.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$132.08B | +14.9% | +46.2% | 30.4 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.15B | +4.6% | +20.8% | 20.0 | 2.3% |
|
ARGX
Argenx SE
|
$62.33B | +19.2% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.54B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Aug 7, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRB | +0.3% | +20.1% | -5.1% | -5.5% | -36.0% |
| SPY | +0.1% | -1.1% | +15.3% | -0.6% | +11.8% |
| vs SPY | +0.2% | +21.2% | -20.4% | -4.9% | -47.8% |